Roche Acquires Medingo Solo Patch Pump: Begin the ‘Usability Wars’?

April 14th, 2010 admin

I’m sure many of you heard the news yesterday that Roche Diabetes has acquired Israel-based Medingo, makers of the much-anticipated Solo insulin patch pump — a would-be direct competitor to the OmniPod tubeless pumping system. Roche paid $160 million for the small company and its technology, which is a drop in the bucket in industry terms.


Originally posted on DiabetesMine

 
  Related Posts
Sizing Up the Solo
Show and Tell today, Friends! I received my demo kit of the Solo tubeless insulin pumping system the other day. That’s the would-be competitor to OmniPod which was acquired by Roche Diabetes last month. It’s not yet on the market — in fact, not slated to be available until 2012, but you can order a free sample  Read More →
Pump & Infusion Set Innovations from NiliMedix
You heard of Medingo, right? The Israeli start-up company whose new patch pump technology was recently acquired by Accu-Chek/Roche Diabetes? Well, there’s another Israeli start-up that’s presumably hoping to beat a similar path.  The company is called NiliMedix, based in the country’s Haifa District. They’re developing both... 
NEWSFLASH: Medtronic’s New Next-Gen Pump + CGM OK’d by the FDA
Happy St. Patrick’s Day, again.  See this morning’s post with some wee silliness on that. A quick newsflash on this lovely green day: this morning Medtronic has announced that it has received FDA approval for its new Paradigm Revel combination insulin pump/continuous glucose monitor, which they’re calling “the industry’s... 
Ipsen’s Partner Roche Announces Amendment Of The Trial Protocols For The Taspoglutide Phase III Programme
Ipsen (Paris:IPN) (Euronext: IPN – ADR: IPSEY), a global biopharmaceutical group, announced that its partner Roche announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen’s... 
Ipsen’s Partner Roche Announces That Taspoglutide Meets Its Primary Endpoint In A Key Phase III Clinical Trial
Ipsen (Paris:IPN) (Euronext: FR0010259150; IPN), a global biopharmaceutical group, today announced that its partner Roche has disclosed results of the phase III T-emerge 3 study in patients with diabetes with taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence. Taspoglutide originating from Ipsen’s... 
A Techie Type 1 Reviews the New Medtronic “Revel” Insulin Pump + CGM System
Technology blogger and Type 1 diabetic Scott Hanselman works for Microsoft, and is quite famous in software developer circles.  As it happens, he’s been wearing the brand new “Revel” combo Insulin Pump and Continuous Glucose Monitor (CGM) system from Medtronic for six days now, and has just posted his thoughts on his tech blog,... 
Chasing the OmniPod: Patch Me If You Can
Last week, I spent a little bit of time at the JP Morgan Healthcare Conference, a nearly-thirty-year-old annual gathering that’s become “the health care industry’s premier financial event, giving more than 330 companies a chance to make formal pitches to institutional investors.”  Due to a houseful of sickies at home, I wasn’t... 
Thinking About a New Pump
When I started writing this post I had my years mixed up and really thought that in January 2011 I’d be on the hunt for a new pump, but after doing some checking, I realized I have 18 months left before my warranty on Toohey expires. Nonetheless, I’m still already thinking about the pump-related decisions that I’ll face in January... 
Quick Brief: the Roche Social Media Summit
Thirty-seven diabetes bloggers and online advocates convened here in Florida today, hosted by Roche Diabetes, for the second annual Social Media Summit — a rare in-person gathering where we can exchange ideas over advocacy efforts and discuss how we’d like to “change the world,” or at least diabetes care in the United States. This... 
SiDMAP Technology Used To Characterize Novel Drug For Type 2 Diabetes
SiDMAP, LLC, a privately held life-science company that provides metabolomics research services to the pharmaceutical and biotechnology industries and the academic biomedical research community worldwide, announced results of a study conducted in collaboration with scientists at Roche (Nutley, NJ), a leading pharmaceutical company, on a novel Roche... 
  Related Tweets from Twitter
Bubenreuth (Apotheke-pharma24)  : Apotheke: ACCU CHEK Safe T Pro Uno II Lanzetten http://url4.eu/7Adxq..
Updated : 2010-09-03T19:00:02Z   |  Reply  |  View Tweet
Bubenreuth (Apotheke-pharma24)  : Angebote-in-Bubenreuth ACCU CHEK Safe T Pro Uno II Lanzetten http://url4.eu/7Ae0k..
Updated : 2010-09-03T18:59:09Z   |  Reply  |  View Tweet
pharmacy22 (mani)  : accu chek.......http://bit.ly/c56RWq..
Updated : 2010-09-03T18:38:27Z   |  Reply  |  View Tweet
pharmacy22 (mani)  : accu-chek-compact-plus-blood-glucose-meter...http://bit.ly/a2FiSP..
Updated : 2010-09-03T18:36:51Z   |  Reply  |  View Tweet
RotoTok (Rob Muller)  : RT @accuchek_ca Accu-Chek Diabetes Link - Diabetes Management: Breaking the Stress Cycle http://bit.ly/b5C6xq..
Updated : 2010-09-03T18:33:54Z   |  Reply  |  View Tweet
  Related News from Digg
No comments yet.

Spam Protection by WP-SpamFree

TOP